A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19 in Healthy Adults
Latest Information Update: 04 Jan 2024
At a glance
- Drugs COVID-2019 DNA vaccine-Immuno Cure 3/The University of Hong Kong (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
Most Recent Events
- 26 Jan 2022 Status changed from not yet recruiting to recruiting.
- 11 Nov 2021 New trial record